Previous Close | 3.5300 |
Open | 3.5500 |
Bid | 3.3300 x 900 |
Ask | 3.3600 x 900 |
Day's Range | 3.3250 - 3.7400 |
52 Week Range | 3.3250 - 18.4300 |
Volume | |
Avg. Volume | 729,246 |
Market Cap | 237.193M |
Beta (5Y Monthly) | 0.25 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.9800 |
Earnings Date | May 10, 2023 - May 15, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for KZR
SOUTH SAN FRANCISCO, Calif., March 14, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.
SOUTH SAN FRANCISCO, Calif., March 13, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT.
SOUTH SAN FRANCISCO, Calif., March 06, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30 pm ET/1:30 pm PT.